Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy

Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.

(2020) Laura M. Spring et al.   CLINICAL CANCER RESEARCH

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher

(2020) Sung Jun Ma et al.   JAMA Network Open

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

(2020) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival

(2019) Maiko Okano et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

(2019) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy

(2019) Joseph A. Sparano et al.   JAMA Oncology

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy

(2018) Alison M. Pease et al.   ANNALS OF SURGICAL ONCOLOGY

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

(2016) John M. S. Bartlett et al.   JNCI-Journal of the National Cancer Institute

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

(2016) Fatima Cardoso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

(2016) John M. S. Bartlett et al.   JNCI-Journal of the National Cancer Institute

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

(2014) Pat Whitworth et al.   ANNALS OF SURGICAL ONCOLOGY

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

(2012) A. Prat et al.   ANNALS OF ONCOLOGY

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY

The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States

(2008) Karl Y. Bilimoria et al.   ANNALS OF SURGICAL ONCOLOGY